# CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma

> **NCT02362165** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 236 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT02362165
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04
- **Primary completion:** 2018-04
- **Final completion:** 2018-05
- **Target enrollment:** 236 (ESTIMATED)
- **Last updated:** 2016-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02362165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02362165, "CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02362165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*